Insulet Corp.

Insulet Corp. has faced notable stock volatility, with significant declines over various timeframes, including a 43.7% drop year-to-date. Despite a long-term growth in net sales, the company reported a net profit decline and a low Return on Capital Employed, indicating profitability challenges. High institutional ownership reflects strong investor support.

Insulet Corp. has reached a new 52-week low, reflecting a significant decline in its stock price over the past year. Despite a strong market capitalization and healthy long-term sales growth, recent financial metrics indicate challenges, including a high price-to-earnings ratio and a decline in net profit.

Insulet Corp. has reached a new 52-week low, reflecting a downturn in its stock performance amid a contrasting rise in the S&P 500. The company, with a market cap of USD 15,815 million, shows strong long-term growth in sales and profits but has experienced a recent decline in net profit.

Insulet Corp., a small-cap company in the Pharmaceuticals & Biotechnology sector, has a notably high P/E ratio of 46, indicating a premium valuation compared to peers. Despite this, the company has experienced significant stock declines, with a year-to-date return of -35.66%, contrasting with the S&P 500's positive performance.

Insulet Corp. has reached a new 52-week low, reflecting a challenging performance over the past year. Despite strong long-term growth rates in net sales and operating profit, the company has struggled with profitability. Its market capitalization stands at approximately USD 15.8 billion, with high institutional holdings.

Insulet Corp. has reached a new 52-week low, reflecting a challenging period despite a long-term growth trajectory in net sales and operating profit. The company faces profitability issues, with a notable decrease in net profit and a low return on capital employed, while maintaining high institutional holdings.

Insulet Corp. has reached a new 52-week low, reflecting ongoing challenges in a competitive market. Despite a healthy long-term growth trajectory, the company has struggled with profitability and underperformed compared to the S&P 500. Its low debt-to-equity ratio indicates a conservative leverage approach, while institutional holdings remain high.

Insulet Corp. has reached a new 52-week low, reflecting a significant decline in its stock price over the past year. Despite a market capitalization of USD 15,815 million and healthy growth in net sales, the company faces challenges with declining net profit and mixed financial metrics.

Insulet Corp. has reached a new 52-week low, reflecting ongoing challenges despite a year-on-year performance increase. The company has experienced a significant drop in net profit and a low return on capital employed. While long-term growth remains strong, recent metrics indicate a need for strategic reassessment.

Insulet Corp., a small-cap in the Pharmaceuticals & Biotechnology sector, has experienced a valuation adjustment, reflected in its elevated P/E ratio of 46. Despite strong operational metrics, including a 27.05% ROCE, the company's stock has underperformed compared to the S&P 500, declining 27.16% year-to-date.

Insulet Corp. has reached a new 52-week low, reflecting a significant decline in its stock price over the past year. Despite a strong market capitalization and healthy long-term sales growth, recent financial metrics indicate challenges, including a notable decrease in net profit and high valuation relative to earnings.

Insulet Corp. has reached a new 52-week low, reflecting a challenging year with a significant decline in stock performance compared to the S&P 500. Despite strong long-term growth in sales and operating profit, recent financial metrics indicate concerns regarding profitability and management efficiency, alongside a notable drop in net profit.

Insulet Corp. has reached a new 52-week low, reflecting a significant decline from its previous high. Despite strong long-term growth in net sales and operating profit, the company's stock performance has lagged behind the S&P 500, with challenges in management efficiency and profitability impacting returns.

Insulet Corp. has faced a significant stock decline, with notable decreases over the past week and month. Despite long-term growth in net sales and operating profit, the company struggles with low profitability metrics and has consistently underperformed compared to the S&P 500, indicating ongoing market challenges.

Insulet Corp. has reached a new 52-week low, contrasting with its previous high. The company has experienced a year of underperformance compared to the S&P 500, despite strong sales growth and operating profit increases. Financial metrics reveal challenges in profitability and a complex market environment.

Insulet Corp., a midcap in the Pharmaceuticals & Biotechnology sector, has shown strong performance with a 37.10% return over the past year, significantly outperforming the S&P 500. Current stock price is $325.80, reflecting recent market evaluations amid mixed technical indicators and a notable trading range.